Tumors induce de novo steroid biosynthesis in T cells to evade immunity

Bidesh Mahata(University of Cambridge), Jhuma Pramanik(Wellcome Sanger Institute), Louise van der Weyden(Wellcome Sanger Institute), Krzysztof Polański(Wellcome Sanger Institute), Gozde Kar(European Bioinformatics Institute), Angela Riedel(Hutchison/MRC Research Centre), Xi Chen(Southern University of Science and Technology), Nuno A. Fonseca(European Bioinformatics Institute), Kousik Kundu(University of Cambridge), Lia S. Campos(Wellcome Sanger Institute), Edward J. Ryder(Wellcome Sanger Institute), Graham Duddy(Wellcome Sanger Institute), Izabela Walczak(Wellcome Sanger Institute), Klaus Okkenhaug(University of Cambridge), David J. Adams(Wellcome Sanger Institute), Jacqueline D. Shields(Hutchison/MRC Research Centre), Sarah A. Teichmann(University of Cambridge)
Nature Communications
July 17, 2020
Cited by 332Open Access
Full Text

Abstract

Tumors subvert immune cell function to evade immune responses, yet the complex mechanisms driving immune evasion remain poorly understood. Here we show that tumors induce de novo steroidogenesis in T lymphocytes to evade anti-tumor immunity. Using a transgenic steroidogenesis-reporter mouse line we identify and characterize de novo steroidogenic immune cells, defining the global gene expression identity of these steroid-producing immune cells and gene regulatory networks by using single-cell transcriptomics. Genetic ablation of T cell steroidogenesis restricts primary tumor growth and metastatic dissemination in mouse models. Steroidogenic T cells dysregulate anti-tumor immunity, and inhibition of the steroidogenesis pathway is sufficient to restore anti-tumor immunity. This study demonstrates T cell de novo steroidogenesis as a mechanism of anti-tumor immunosuppression and a potential druggable target.


Related Papers

No related papers found

Powered by citation graph analysis